CAMBRIDGE, Mass., SHANGHAI and SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Blueprint Medicines Corporation (NASDAQ:BPMC) today announced an ...
-- Collaboration accelerates and expands global development of Blueprint Medicines’ next-generation EGFR inhibitors with plans to bring clinical trials of BLU-945 and BLU-701 to Greater China-- While ...
-- Collaboration accelerates and expands global development of Blueprint Medicines' next-generation EGFR inhibitors with plans to bring clinical trials of BLU-945 and BLU-701 to Greater China -- -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback